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Abstract The human airways are protected from pathogenic
colonization by a blanket of fluid impregnated with innate
antimicrobial effector molecules. Among several previously
uncharacterized components, we isolated a peptide that had
activity primarily targeting Gram-negative bacteria. We named
the peptide ‘calcitermin’ since its amino acid sequence and mass
were equivalent to the 15 C-terminal residues of the S100
protein, calgranulin C. The antimicrobial activity of calcitermin
was enhanced in acidic buffers (pH 5.4) and in the presence of
micromolar concentrations of ZnCl2. Analysis revealed a
putative zinc-binding consensus sequence as well as an K-helical
conformation in structure-promoting solvents. ß 2001 Federa-
tion of European Biochemical Societies. Published by Elsevier
Science B.V. All rights reserved.
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1. Introduction
Antimicrobial peptides are widely distributed molecular ef-
fectors of innate immunity. Several families of peptides exist
that display similar mechanisms of action against microbes.
Many are broad-spectrum microbicides that target Gram-pos-
itive and Gram-negative bacteria as well as fungi and some
enveloped viruses [1^3]. Antimicrobial peptides share cationic
charge and hydrophobicity at physiologic pH, features that
facilitate peptide binding and insertion into microbial mem-
branes. Some peptides then aggregate to form pores, and
death ensues once a critical number of pores have formed
[4,5].
Epithelia in the human airways, from the nasal aperture to
the alveoli, are covered in a protective ¢lm of serous and
mucous £uid containing a number of antimicrobial proteins,
including lysozyme, lactoferrin and secretory leukoproteinase
inhibitor (reviewed in [3]). Recently, two L-defensin antimicro-
bial peptides (HBD-1 and HBD-2) and one cathelicidin (LL-
37) have been found in £uid from the lower and upper air-
ways [6^8]. Additionally, neutrophils can be recruited into the
airways during infection and in£ammation and secrete mole-
cules such as the abundant K-defensins (HNPs) [9^11]. The
combined e¡ects of antimicrobial proteins and peptides within
the airways contribute to an e¡ective antibiotic shield.
The S100 family of calcium-binding proteins currently com-
prises 19 members that are di¡erentially expressed in a variety
of tissues. The activities of S100 proteins vary widely and
include calcium-dependent roles in in£ammation and the reg-
ulation of cellular processes, including proteins phosphoryla-
tion, cell proliferation, structural membrane and cytoskeletal
organization [12]. Calgranulin, which belong to the S100 fam-
ily, have been shown to be antimicrobial. Calgranulin A and
B from the heterodimer calprotectin, with demonstrated fun-
gicidal and bactericidal activities [13,14]. Calgranulin C is a
newly described member of the family produced by neutro-
phils and monocytes [15] and keratinocytes [16,17] and has
only been reported to have antiparasitic activity [16]. The
overexpression of calgranulin C in lesional psoriasis suggests
a role in in£ammatory host defense [18].
From our initial observations, human airway secretions
contain a number of uncharacterized antimicrobial molecules.
We therefore probed for (poly)peptides that contribute to the
overall microbicidal activity of human nasal £uid. We report
here the discovery and characterization of a novel 15-residue
antimicrobial peptide, which is a putative C-terminal cleavage
fragment of calgranulin C.
2. Materials and methods
2.1. Isolation and puri¢cation of antimicrobial peptides from human
nasal secretions
Nasal secretions were collected from healthy volunteer donors ac-
cording to a protocol approved by the UCLA Institutional Review
Board. From most donors, nasal secretions were collected by vacuum-
aided suction, without chemical stimulation (described in [11]), to
avoid introducing foreign substances into the nasal £uids. Gentle ma-
nipulation of a narrow catheter tip inside the nasal passageways
mildly stimulated nasal secretions. 40 ml of nasal £uid were solubi-
lized by 1:5 dilution in 5% acetic acid for 18 h at 4‡C. Fluid was
cleared by centrifugation at 21 000Ug for 15 min and the resulting
supernatant was applied to SepPak Vac 15-g C18 cartridges (12%
carbon, 12.5-nm pore size, 80-Wm particle size), and eluted with
40% acetonitrile/0.1% tri£uoroacetic acid (TFA). The vacuum-concen-
trated eluate was resuspended in 0.01% acetic acid, and subjected to
strong cation-exchange HPLC (Vydac, The Separations Group, Hes-
peria, CA, USA, 5-Wm particle size, 9.8U100 mm; linear AB gra-
dients where A is 5% acetonitrile/25 mM NaP, pH 6.0, and B is 5%
acetonitrile/25 mM NaP, pH 5.0/1 M NaCl, with a 60-min gradient at
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16.7 mM NaCl min31 and 1 ml min31). Peak fractions that exhibited
antimicrobial activity by radial di¡usion assay (RDA) were applied to
a Vydac 218TP C18 (5-Wm particle size, 4.6U250 mm) reverse-phase
HPLC column (linear AB gradient where A is H2O/0.1% TFA, and B
is acetonitrile/0.1% TFA, with a 120-min gradient at 0.5% acetonitrile
min31 and 1 ml min31). Peak fractions were further puri¢ed on a
microbore Vydac C18 column (5-Wm particle size, 2.3U100 mm) using
a linear three-ramp gradient of water^ACN (0.3 ml min31 ; see Fig.
1A). A single peak eluting at 30% ACN contained calcitermin. Ma-
trix-assisted laser desorption ionization-time-of-£ight mass spectrom-
etry (MALDI-TOF) and N-terminal Edman microsequencing of pu-
ri¢ed natural calcitermin were performed at the Emory University
School of Medicine Microchemistry Facility (Jan Pohl, Ph.D., Direc-
tor).
2.2. Calcitermin synthesis and puri¢cation
Peptides were synthesized at a 0.25-mmol scale with a Perkin-Elmer
ABI 431 A Synthesizer, using pre-derivatized polyethylene glycol
polystyrene glutamic acid resin (PerSeptive Biosystems, Framingham,
MA, USA), FastMoc1 chemistry [19], and double coupling for all
residues. The peptide was then puri¢ed by reverse-phase HPLC. Since
calcitermin contains a tyrosine residue, its concentration was deter-
mined using an extinction coe⁄cient of 1490 M31 cm31 [20].
2.3. CD spectroscopy
Circular dichroism (CD) measurements were performed with an
AVIV 62DS spectropolarimeter (AVIV Associates, Lakewood, NJ,
USA) that was calibrated with (+)-10-camphorsulfonic acid (1 mg
ml31) in a 1-mm-path length cell [21]. The peptide^solvent solutions
were measured in 0.1-mm light path demountable cells that were
scanned from 260 nm to 190 nm at a rate of 10 nm min31 with
0.2-nm intervals. The results were expressed as the mean residual
ellipticity (MRE), [3]MRE (degree cm2 dmol31).
2.4. Atomic absorption
Nasal secretions were sonicated using a microtip dismembranator
for 20 s, and ‘wet-ashed’ in concentrated HNO3 (trace metal grade,
Fisher Scienti¢c): 100 Wl of each sample received 900 Wl of acid. These
sat at ambient temperature overnight. For quality assurance, a recon-
stituted human serum standard (Utak Bi-Level Trace Elements, Utak
Laboratories Inc., Valencia, CA, USA) and methods blanks were
analyzed simultaneously. After acid treatment, 100 Wl of each sample
was diluted with Mg(NO3)2 matrix modi¢er to a volume of 1.0 ml and
analyzed in a Perkin-Elmer 503 atomic absorption spectrophotometer
(Foster City, CA, USA) ¢tted with a graphite furnace atomizer and a
autosampler set for 25-Wl sample injections. The minimum detection
level (MDL), calculated as 3Ustandard deviation of method blanks,
was 0.98 ng ml31. The human serum standard was 95 þ 5 ng ml31,
well within the acceptable range of 94 þ 19 ng ml31.
2.5. Microbes and culture conditions
Escherichia coli ML-35p, Listeria monocytogenes EGD, Staphylo-
coccus aureus (human clinical isolate, UCLA Clinical Microbiology
Facility), Candida albicans (human clinical isolate), and Staphylococ-
cus epidermidis (human clinical isolate, used for in vitro assays), were
cultured 18 h at 37‡C in 50 ml trypticase soy broth (TSB = 3% weight
per water volume (w/v); all strains described in [22]). The Pseudomo-
nas aeruginosa strain is a mucoid isolate [23] from a cystic ¢brosis
patient (isolate generously donated by Dr. M.J. Welsh, University of
Iowa, IA, USA). Immediately prior to use each strain was subcultured
in 50 ml TSB at either 1:100 (L. monocytogenes, S. aureus, S. epider-
midis, C. albicans and P. aeruginosa) or 1:1000 (E. coli) dilution for
2.5 h at 37‡C in an environmental shaking incubator (250 rpm) to
obtain microbes in mid-logarithmic growth phase. Subcultures were
then centrifuged at 1400Ug for 10 min, washed once in 10 mM so-
dium phosphate (pH 7.4 or pH 5.4), and diluted to their desired
concentrations in the same bu¡er. For bacteria, an OD625 = 1.0 was
equivalent to 2.5U108 CFU ml31. For fungi, an OD450 = 1.0 was
equivalent to 2.5U108 CFU ml31.
2.6. Gel overlay assay
The gel overlay assay was performed as described previously [24].
Brie£y, acetic acid-extracted nasal £uids were separated by acid^urea-
polyacrylamide gel electrophoresis (AU-PAGE). The gel was washed
20 min in 10 mM sodium phosphate, pH 7.4, then placed on a pre-
made 1% agarose plate containing 10 mM sodium phosphate with 100
mM NaCl, pH 7.4, 1% TSB (0.03% w/v), and 4U106 L. monocyto-
genes or E. coli. The plate was then incubated at 37‡C for 3 h to allow
the proteins and peptides in the polyacrylamide gel to di¡use into the
underlying bacterial layer. The polyacrylamide gel was then removed
and the bacterial layer was overlaid with a nutrient layer that con-
tained double-strength TSB (6% w/v) in 1% agarose. Clear zones with-
out bacterial growth represented antibacterial activity. Duplicate AU-
PAGE gels were electrophoresed and Coomassie-stained to correlate
antibacterial activity with protein bands.
2.7. RDA
RDA were performed as described previously [24,25]. Brie£y, the
underlayer consisted of 1% agarose and 1% TSB (0.03% w/v) in 10
mM sodium phosphate bu¡er, pH 5.4. Overlay consisted of double-
strength TSB and 1% agarose in 10 mM sodium phosphate bu¡er, pH
5.4. 4U106 bacteria or fungi were mixed with 10 ml of underlayer gel
solutions kept molten at 48‡C and poured into 100 cm2 square petri
dishes. A series of 3.2-mm diameter wells were punched after the
agarose solidi¢ed, and 5 Wl of calcitermin was added into designated
wells. Plates were incubated at 37‡C for 3 h to allow for peptide
di¡usion. The microbe-laden underlayer was then covered with 10
ml of molten overlay, and the plates were allowed to harden. Anti-
microbial activity was identi¢ed as a clear zone around the well absent
of microbial growth after 18 h incubation at 37‡C. The activity was
represented in radial di¡usion units (RDU) de¢ned as: (diameter of
clear zone in mm ^ 3.2 mm)U10. Assays were performed in duplicate
and repeated at least once.
2.8. Colony-forming unit (CFU) assay
Bacterial (OD625 = 0.2) or yeast (OD450 = 1.0) were diluted 100-fold
in 10 mM sodium phosphate bu¡er (pH 5.4 or pH 7.4) for use in a
microassay. The test sample consisted of 3 Wl of either bacterial or
yeast dilution plus 12 Wl of calcitermin in 10 mM sodium phosphate
bu¡er (pH 5.4 or pH 7.4)+1.3% TSB for each condition, which al-
lowed triplicates of two time points (0- and 3-h incubation). Separate
tubes with 3 Wl bacteria or yeast and 12 Wl of bu¡er/1.3% TSB were
used as controls for microbial growth. Each well of a 72-well Terasaki
microtiter plate (Nalge Nunc, International, Denmark) was loaded
with 1.5 Wl liquid wax (MJ Research, Watertown, MA, USA) to
prevent evaporation. 2 Wl of the test sample was loaded into each of
six wells by pipetting directly underneath the liquid wax. The entire
plate was incubated at 37‡C. To recover the incubated £uid at the
speci¢ed time points, wells were washed thoroughly with 45 Wl of
bu¡er and the wash was placed on ice in a microcentrifuge tube.
The £uid was then plated on tryptic soy agar (TSA) plates to count
CFUs the following day.
3. Results
3.1. Human nasal secretions contain unidenti¢ed antimicrobial
peptides
In our analysis of the natural antimicrobial properties of
minimally manipulated nasal secretions [11] we used a gel
overlay technique that imprints proteins, electrophoresed by
AU-PAGE, onto a lawn of E. coli or L. monocytogenes. Mul-
tiple microbicidal bands were detected that did not corre-
spond to known antimicrobial (poly)peptides (data not
shown). Reducing the ionic strength further increased the
number of polypeptide bands that were measurably antimicro-
bial by gel overlay analysis (data not shown). The pattern of
activity depended on the target microbe species. These initial
studies served as the impetus to uncover novel antimicrobial
polypeptides in human nasal secretions.
3.2. Isolation of an antimicrobial peptide from nasal secretions
Human nasal secretions were analyzed for antimicrobial
peptides by methods successfully used for ¢sh mucus secre-
tions [26] and amphibians [27]. Acidi¢ed nasal secretions were
subjected to batch reverse-phase separation (C18 SepPak),
cation-exchange HPLC, and two rounds of reverse-phase
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HPLC. The chromatogram from the ¢nal reverse-phase
HPLC puri¢cation is shown in Fig. 1A, with the arrow indi-
cating an antimicrobial peak fraction as tested by RDA
against E. coli (10 mM sodium phosphate, pH 5.4). This frac-
tion was subjected to mass spectrometry (Fig. 1B) yielding a
mass of 1688.9 Da. Protein microsequencing revealed the full
amino acid sequence shown in Fig. 1C. The measured mass
(1688.9 Da) corresponded precisely to the theoretical mass of
the amino acid sequence (1688.95 Da), and was 100% identi-
cal to the terminal 15 residues of calgranulin C (Fig. 1C)
(calgranulin C SwissProt Accession #P80511). We thus named
this peptide, ‘calcitermin’.
3.3. Synthesis and conformational studies
We synthesized calcitermin using FastMoc1 chemistry and
puri¢ed the peptide to s 98% using C18 reverse-phase HPLC.
After this step, the peptide appeared homogeneous and its
mass, as con¢rmed by MALDI-TOF mass spectrometry mea-
surement (1688.7 Da), agreed well with its theoretical mass
(1688.95 Da). Synthetic and native calcitermin (5 Wl of a
355-WM solution) were each tested using a RDA against E.
coli (10 mM sodium phosphate, pH 5.4) and found to be
equally antimicrobial (data not shown). Subsequent analyses
were performed on synthetic calcitermin.
In CD spectroscopy measurements, K-helical secondary
structures were revealed by double dichroic minima at 208
and 222 nm [28,29]. Our studies revealed a largely random
coil structure in 25 mM sodium phosphate, pH 6.0 (Fig. 2).
Once structure-promoting membrane mimetics were added,
such as 50% tri£uoroethanol (induces helical conformations)
or 10% SDS micelles, calcitermin showed enhanced K-helical
conformation (Fig. 2). The transition from random coil to
K-helix has been shown by CD spectroscopy of other linear
human antimicrobial peptides, including the cathelicidin LL-
37 [30].
3.4. Antimicrobial activity of calcitermin is enhanced at acidic
pH and in the presence of zinc
Calcitermin (1^50 Wg ml31) was tested in a CFU assay
against E. coli, P. aeruginosa, C. albicans, S. epidermidis, S.
aureus, and L. monocytogenes. When assayed in 10 mM so-
dium phosphate bu¡er, pH 7.4, calcitermin could not kill E.
coli (Fig. 3B) or any of the other strains tested (data not
shown). However, when the acidity of the medium was in-
creased (10 mM sodium phosphate, pH 5.4), 50 Wg ml31 cal-
Fig. 1. Puri¢cation of an antimicrobial peptide from human nasal
secretions. A: Absorbance at 215 nm for the ¢nal reverse-phase
HPLC puri¢cation. Antimicrobial peptide is represented by an ar-
row. Acetonitrile gradient is given by a dashed line. B and inset:
MALDI-TOF mass spectroscopy of the native peptide indicating
the major product from puri¢cation was 1688.9 Da. The sequences
of calcitermin, and the terminal 14 or 15 residues of human calgran-
ulin A and C and porcine calgranulin C are shown in C. Identical
residues are connected by vertical lines. Calcitermin was 100% iden-
tical to human calgranulin C, 53% identical to human calgranulin
A, and 47% identical to porcine calgranulin C. Asterisks indicate
histidine residues, and underlined residues indicate zinc-binding con-
sensus sequences (HXXXH).
Fig. 2. CD spectrometry. CD was measured in 25 mM sodium
phosphate bu¡er, pH 6.0 (curve a), 25 mM sodium phosphate, pH
6.0+50% tri£uoroethanol (curve b), and 10% SDS+10 mM sodium
phosphate, pH 6.0 (curve c). Note the transition from a random
coil (curve a) to K-helical spectra (curves b and c).
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citermin was active against E. coli (Fig. 3A) and P. aeruginosa
and C. albicans, but not S. aureus and L. monocytogenes (data
not shown). As reported previously with clavanins [22], reduc-
ing the pH protonates calcitermin’s three histidine residues.
Since the pH of in£ammatory £uid often becomes acidic [31],
the concomitant increase in cationic charge likely enhances
the peptide’s interaction with negatively charged groups on
bacterial surfaces.
We then tested the activity of calcitermin in a sensitive
RDA. Similar to CFU assays, calcitermin was not active
against any tested microorganisms in 10 mM sodium phos-
phate, pH 7.4 (data not shown), and only moderately active
against E. coli (Fig. 3C) and inactive against L. monocytogenes
(Fig. 3D) in 10 mM sodium phosphate, pH 5.4. The addition
of 100 mM NaCl, 1 mM MgCl2 1 mM CaCl2, or 1 mM
FeC6H5O7 reduced or totally inhibited the active of calciter-
min against E. coli and L. monocytogenes (Fig. 3C,D). How-
ever, since calcitermin contains a putative zinc-binding do-
main (Fig. 1C), we admixed calcitermin and either 10 WM
or 100 WM ZnCl2 prior to analysis by RDA. ZnCl2 increased
the antimicrobial activity of calcitermin against E. coli (Fig.
3C) and most notably against L. monocytogenes (Fig. 3D).
However, ZnCl2 did not a¡ect the activity of calcitermin
against C. albicans (data not shown).
Utilizing atomic absorption, we next measured the concen-
tration of zinc in human nasal £uids to determine if zinc levels
in vivo were high enough to synergize with calcitermin. Three
types of donors were tested: healthy donors (n = 5), cystic ¢-
brosis patients (n = 4), and nasal carriers of S. aureus (n = 3).
Zinc concentrations ranged from below the detection limit
(6 0.98 ng ml31) to 83 ng ml31, with the cystic ¢brosis sam-
ples at the high end. However, we did not detect signi¢cant
di¡erences among the three groups of donors (Student’s t-test
with Bonferroni adjustment; individual datapoints not
shown). It is notable that 83 ng ml31 (12.8 WM) zinc is su⁄-
cient to synergize with calcitermin against L. monocytogenes,
which required only 10 WM ZnCl2 for synergy in our in vitro
assays (Fig. 3D).
4. Discussion
Human airways are exposed to colonization by inhaled
pathogens, and thus the innate defense mechanisms in the
airways must be highly e¡ective. Many antimicrobial polypep-
tides are present in the airways, including larger and more
abundant molecules, such as lysozyme and lactoferrin, and
smaller and less abundant moieties, such as defensins. How-
ever, our studies indicated that additional as yet uncharacter-
Fig. 3. Antimicrobial activity of calcitermin is dependent on pH and cations. CFU assays were performed with 0, 1, 10 or 50 Wg ml31 calciter-
min against E. coli in 10 mM sodium phosphate at (A) pH 5.4 and (B) pH 7.4. Calcitermin was microbicidal only in mildly acidic conditions.
Error bars represent S.E.M. (n = 3). The e¡ect of cations on the antimicrobial activity of calcitermin was also tested. Radical di¡usion assays
were performed on 5 Wg of calcitermin against (C) E. coli and (D) L. monocytogenes either alone (in 10 mM sodium phosphate, pH 5.4) or in
the presence of 100 mM NaCl (Na), 1 mM MgCl2 (Mg), 1 mM CaCl2 (Ca), 1 mM FeC6H5O7 (Fe), 10 WM ZnCl2 (Zn (L)), 100 WM ZnCl2
(Zn (H)). Lower (L) and higher (H) concentrations of ZnCl2 dramatically increased the activity of calcitermin. Asterisk indicates that 100 WM
ZnCl2 alone was weakly antimicrobial (6 10 RDU). Error bars represent S.E.M. (n = 3).
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ized antimicrobial substances contributed to the activity of
nasal £uid [11].
Although calcitermin is the ¢rst antimicrobial fragment of a
larger parent protein discovered in upper airway secretions,
several studies have reported that segments of proteins have
potent antimicrobial activity. Lactoferricin, a pepsin-digested
fragment of lactoferrin, is broadly antimicrobial and has been
shown to synergize with other polypeptides such as lysozyme
[32]. Fragments of lysozyme have been reported to contain
direct antibacterial activity independent of its muramidase
action [33]. In fact, the calgranulin family of proteins may
actually be pro-proteins similar to inactive pro-defensins and
pro-cathelicidins that, when enzymatically cleaved, liberate
active defensin and cathelicidin molecules, respectively [3]. In-
terestingly, histone fragments have been known for decades as
potent cationic antimicrobials [34^36]. We also detected his-
tone fragments in nasal secretions (A.M.C. and T.G., unpub-
lished data), lending credence to the role of processed proteins
in innate host defense.
The increase in activity of calcitermin may result from a
zinc-induced conformational change that stabilizes peptide
structure. Indeed, the structure and moderate microbicidal
activity of calcitermin are reminiscent of the cationic, histi-
dine-rich human salivary histatins. Most histatins contain at
least one C-terminal zinc-binding consensus sequence, and
through NMR studies zinc has been demonstrated to bind
the zinc-binding consensus sequence of histatin-5 [37,38].
Two-dimensional NMR and Fourier-transformed infrared
and CD spectroscopy indicate that histatins can form mem-
brane-induced K-helical conformations [39]. As with calciter-
min, the antimicrobial activities of several histatins are low at
neutral pH and increase at acidic pH [40]. However, histatins
have not been identi¢ed in the airways. Calcitermin may serve
as a comparable sentinel molecule of the airways with a role
similar to that of histatins in saliva.
Like calgranulin C, calgranulins A and B also contain zinc-
binding domains in their C-terminal sequence. However, zinc
chelation, rather than zinc binding, has been reported to in-
crease the activity of calprotectin (heterodimer of calgranulins
A and B) [41^43].
Up to 5% of neutrophil cytosolic proteins are calgranulins,
and these proteins are released upon death and lysis of neu-
trophils at in£ammatory sites [44,45]. The concentration of
calgranulins in abscess £uids can approach 20 mg ml31 [42].
Not only does the in£ammatory £uid provide abundant pre-
cursors for the generation of calcitermin, but the pH often
becomes acidic favoring the activity of calcitermin. Under
these or similar conditions, calcitermin may contribute to
the antimicrobial activity of body £uids.
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